Xerclear

Therapy area
Episodic treatment of recurrent labial herpes to prevent cold sores.

In phase
Xerclear was approved by the US FDA on 31 July 2009 for marketing and sales in US.

In October the European regulatory authorities approved marketing authorisation for Xerclear in 14 European countries.

Competitive edge Label in USA – "Acyclovir and Hydrocortisone Cream is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time"

Competitive edge Label in Europe – "Treatment of early signs and symptoms of recurrent herpes labialis (cold sores) to reduce the progression of cold sore episodes to ulcerative lesions in immunocompetent adults and adolescents (12 years of age and older)"

• First treatment of recurrent labial herpes to prevent lesion development.
• Low risk for adverse events